Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Curis, Inc.
Incyte Corporation
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Amgen
Dren Bio
Miltenyi Biomedicine GmbH
Institute of Hematology and Blood Transfusion, Czech Republic
AVM Biotechnology Inc
BeOne Medicines
Therapeutic Advances in Childhood Leukemia Consortium
Children's Hospital of Philadelphia
M.D. Anderson Cancer Center
Roswell Park Cancer Institute
M.D. Anderson Cancer Center
BeOne Medicines
Janssen Research & Development, LLC
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Stanford University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Janssen Research & Development, LLC
Genmab
Janssen Pharmaceutical K.K.
University of Florida
Chordia Therapeutics, Inc.
M.D. Anderson Cancer Center
AstraZeneca
Nurix Therapeutics, Inc.
Beijing Biotech
National Institutes of Health Clinical Center (CC)
Genmab
Ohio State University Comprehensive Cancer Center
Genmab
PedAL BCU, LLC
National Institutes of Health Clinical Center (CC)
Bristol-Myers Squibb
AstraZeneca
Beth Israel Deaconess Medical Center
Nationwide Children's Hospital
Novartis
CRISPR Therapeutics
Eastern Cooperative Oncology Group
M.D. Anderson Cancer Center
AvenCell Therapeutics, Inc.
Daiichi Sankyo
Takeda